Engineered Brain Cells Show Promise in Alzheimer’s Treatment

A novel cellular immunotherapy is demonstrating potential in both preventing the formation and reducing existing amyloid plaques in the brains of mice, offering a promising novel avenue for Alzheimer’s disease treatment. Researchers at Washington University School of Medicine have engineered brain cells to act as “super cleaners,” effectively removing harmful proteins associated with cognitive decline.

A New Approach to Alzheimer’s Therapy

Current Alzheimer’s drugs, monoclonal antibodies like lecanemab and donanemab, can modestly extend independent living for patients—approximately 10 months—but require frequent, high-dose infusions and carry risks like amyloid-related imaging abnormalities. This new approach aims to improve efficacy and reduce the burden of treatment.

How CAR-Astrocyte Immunotherapy Works

The research, published in Science on March 5, 2026, utilizes a technique similar to CAR-T cell therapy used in cancer treatment. Instead of modifying T cells, researchers focused on astrocytes—star-shaped brain cells—genetically altering them to target amyloid beta plaques.

A harmless virus is used to deliver a gene coding for a chimeric antigen receptor (CAR) into the astrocytes. This effectively reprograms the astrocytes, transforming them into specialized cells focused on clearing amyloid beta plaques.

Study Results in Mice

The study involved two groups of mice: young mice before plaque formation and older mice with existing plaques. A single injection of the gene therapy yielded significant results:

• Prevention: Young mice treated with the therapy showed no amyloid plaque development by six months of age.
• Reduction: Older mice with existing plaques experienced a roughly 50% reduction in plaque volume after three months.

“This study marks the first successful attempt at engineering astrocytes to specifically target and remove amyloid beta plaques in the brains of mice with Alzheimer’s disease,” said Marco Colonna, MD, the Robert Rock Belliveau, MD, Professor of Pathology at WashU Medicine.

Potential and Future Directions

While promising, this research is still in its early stages. Further investigation is needed to optimize the approach, address potential side effects, and determine its safety and efficacy in humans. However, the results suggest a potential for a single-injection immunotherapy for Alzheimer’s and potentially other neurodegenerative diseases and even brain tumors.

“Consistent with the antibody drug treatments, this new CAR-astrocyte immunotherapy is more effective when given in the earlier stages of the disease,” says co-author David Holtzman, neuroscientist at Washington University.